Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference
May 25 2023 - 7:33AM
Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or
“Inotiv”), a leading contract research organization
specializing in nonclinical and analytical drug discovery and
development services and research models and related products and
services, announced today that Robert Leasure Jr., President and
Chief Executive Officer, and Beth Taylor, Chief Financial Officer,
will present at the Jefferies Healthcare Conference, being held in
New York, NY, from June 7-9, 2023. Management will also be
available for one-on-one meetings.
Event: Jefferies Healthcare
ConferenceLocation: New York
CityPresentation Date: Friday, June 9,
2023Time: 8:30 – 8:55 AM Eastern Time
The webcast presentation will be available for viewing and
replay under the “Investor Relations” tab of the Company's website
at www.inotivco.com.
About the Company Inotiv,
Inc. is a leading contract research organization dedicated to
providing nonclinical and analytical drug discovery and development
services and research models and related products and services. The
Company’s products and services focus on bringing new drugs and
medical devices through the discovery and preclinical phases of
development, all while increasing efficiency, improving data, and
reducing the cost of taking new drugs to market. Inotiv is
committed to supporting discovery and development objectives as
well as helping researchers realize the full potential of their
critical R&D projects, all while working together to build a
healthier and safer world. Further information about Inotiv can be
found here: https://www.inotivco.com/.
This release contains forward-looking statements
that are subject to risks and uncertainties including, but not
limited to, risks and uncertainties related to the impact of recent
events related to NHP matters on the Company’s business,
operations, results, financial condition, cash flows, and assets,
the Company’s ability to comply with covenants under its credit
agreement, Company’s ability to reduce its legal and third party
fees, changes in the market and demand for the Company’s products
and services, the development, marketing and sales of products and
services, changes in technology, industry and regulatory standards,
the timing of acquisitions and the successful closing, integration
and business and financial impact thereof, governmental
regulations, inspections and investigations, claims, investigations
and litigation against or involving the Company, its business
and/or its industry, the impact of site closures and
consolidations, expansion and related efforts, and various other
market and operating risks, including those detailed in the
Company's filings with the U.S. Securities and Exchange
Commission.
Company Contact |
Investor Relations |
Inotiv, Inc. |
The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer |
Devin Sullivan |
(765) 497-8381 |
dsullivan@equityny.com |
btaylor@inotivco.com |
|
Inotiv (NASDAQ:NOTV)
Historical Stock Chart
From Oct 2024 to Nov 2024
Inotiv (NASDAQ:NOTV)
Historical Stock Chart
From Nov 2023 to Nov 2024